The startup develops small chemical molecules and gene therapies aimed at treating neurodegenerative diseases and neuro-orphan conditions. By accelerating the time-to-clinic for effective disease-modifying therapies, the company enhances treatment options for central nervous system disorders.
Funding
$490K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Neurodegenerative diseases and neuro-orphan conditions present significant challenges due to the limited availability of effective, disease-modifying therapies. The lengthy drug discovery and development process further delays the introduction of new treatments for central nervous system disorders.
Solution
Abaxys Therapeutics is a biopharmaceutical company focused on accelerating the development of innovative small molecule and gene therapies for neurodegenerative diseases. The company leverages a data-driven approach, integrating data mining, big data analytics, and bio-imaging to identify promising drug candidates and optimize preclinical development. By utilizing in-silico validation techniques, Abaxys aims to significantly reduce the time-to-clinic for efficacious therapies. Their research focuses on key biological systems involved in neuronal and brain function, including the proteosomal system, neuronal response to stress, and epigenetic gene expression controls, to discover novel therapeutic targets.
Target Audience
The primary target audience includes patients suffering from neurodegenerative diseases and neuro-orphan conditions, as well as pharmaceutical companies seeking innovative therapeutic programs for licensing or co-development.
Features
- Data mining approach for efficient hit identification.
- Big data and simulation for accelerated lead optimization, replacing traditional lab and animal testing with in-silico validation.
- Bio-imaging techniques to monitor drug impact on animal models without sacrificing the animal, enabling longitudinal disease evolution tracking.
- Focus on small molecules and gene therapies.
- Pipeline includes programs targeting Obesity, Parkinson’s disease, and Epilepsy.
- Proprietary technology platform for preclinical drug discovery.
- Disease modeling platform to ensure drug discovery strategy and deliver biomarkers.
- Quantitative high-resolution image analysis for precise assessment of neurotherapeutic efficacy.